Literature DB >> 20936361

In vitro antifungal activity of dihydroxyacetone against causative agents of dermatomycosis.

Cheila Denise Ottonelli Stopiglia1, Fabiane Jamono Vieira, Andressa Grazziotin Mondadori, Tércio Paschke Oppe, Maria Lúcia Scroferneker.   

Abstract

Dihydroxyacetone (DHA), a three-carbon sugar, is the browning ingredient in commercial sunless tanning formulations. DHA preparations have been used for more than 50 years and are currently highly popular for producing temporary pigmentation resembling an ultraviolet-induced tan. In this work, the in vitro antifungal activity of dihydroxyacetone was tested against causative agents of dermatomycosis, more specifically against dermatophytes and Candida spp. The antifungal activity was determined by the broth microdilution method according to the Clinical and Laboratory Standards Institute guidelines for yeasts and filamentous fungi. The data obtained show that the fungicidal activity varied from 1.6 to 50 mg ml(-1). DHA seems to be a promising substance for the treatment of dermatomycosis because it has antifungal properties at the same concentration used in artificial suntan lotions. Therefore, it is a potential low-toxicity antifungal agent that may be used topically because of its penetration into the corneal layers of the skin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20936361     DOI: 10.1007/s11046-010-9370-x

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  19 in total

1.  Dihydroxyacetone. Recent clinical investigative studies.

Authors:  L GOLDMAN; D J BLANEY
Journal:  Arch Dermatol       Date:  1962-06

2.  Staining of skin with dihydroxyacetone.

Authors:  E WITTGENSTEIN; H K BERRY
Journal:  Science       Date:  1960-09-30       Impact factor: 47.728

3.  The physical aspects with respect to water and non-enzymatic browning.

Authors:  T P Labuza; R M Warren; H C Warmbier
Journal:  Adv Exp Med Biol       Date:  1977       Impact factor: 2.622

4.  Determination of MICs of aminocandin for Candida spp. and filamentous fungi.

Authors:  N Isham; M A Ghannoum
Journal:  J Clin Microbiol       Date:  2006-10-04       Impact factor: 5.948

5.  Biochemical characterization of terbinafine-resistant Trichophyton rubrum isolates.

Authors:  Bertrand Favre; Mahmoud A Ghannoum; Neil S Ryder
Journal:  Med Mycol       Date:  2004-12       Impact factor: 4.076

6.  Turbo-PUVA: dihydroxyacetone-enhanced photochemotherapy for psoriasis: a pilot study.

Authors:  C R Taylor; C Kwangsukstith; J Wimberly; N Kollias; R R Anderson
Journal:  Arch Dermatol       Date:  1999-05

Review 7.  The future of onychomycosis therapy may involve a combination of approaches.

Authors:  R J Hay
Journal:  Br J Dermatol       Date:  2001-10       Impact factor: 9.302

8.  In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2004-02       Impact factor: 2.803

9.  In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

10.  In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents.

Authors:  Francesco Barchiesi; Carmela Silvestri; Daniela Arzeni; Giulia Ganzetti; Sefora Castelletti; Oriana Simonetti; Oscar Cirioni; Wojciech Kamysz; Elzbieta Kamysz; Elisabetta Spreghini; Alessandra Abruzzetti; Alessandra Riva; Anna M Offidani; Andrea Giacometti; Giorgio Scalise
Journal:  Med Mycol       Date:  2008-12-27       Impact factor: 4.076

View more
  1 in total

1.  A hypothesis for examining dihydroxyacetone, the active component in sunless tanning products, as a topical prophylactic against SARS-COV-2 transmission.

Authors:  David M Perrin
Journal:  Med Hypotheses       Date:  2020-09-16       Impact factor: 1.538

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.